Merck KGaA Health Care Head Happy With Old And New Mix
Pipeline Will Augment Established Strong Sellers
Executive Summary
The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.
You may also be interested in...
Merck KGaA Ties Up Chord To Advance Cladribine Rare Disease Programs
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.